Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery DiseaseDominick J. Angiolillo, Theodore A. Bass, Joseph A. Jakubowski et al.|Journal of the American College of Cardiology|2014Cited by 181
Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly PatientsDavid Erlinge, Dominick J. Angiolillo, Stefan James et al.|Journal of the American College of Cardiology|2013Cited by 94
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight PatientsDavid Erlinge, Kenneth J. Winters, Jurriën M. ten Berg et al.|Journal of the American College of Cardiology|2012Cited by 83
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseThomas O. Bergmeijer, Paul A. Gurbel, Udaya S. Tantry et al.|Thrombosis and Haemostasis|2014Cited by 32
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patientsHenrik Wagner, David Erlinge, Dominick J. Angiolillo et al.|Journal of Thrombosis and Thrombolysis|2013Cited by 30